Medical expenditures of adult cancer survivors aged <65 years in the United States

Cancer

Volumn 117, Issue 12, 2011, Pages 2791-2800

  Short, Pamela Farley ^a   Moran, John R ^a   Punekar, Rajeshwari ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

cancer survivor; costs of cancer; health expenditures; personal expenditures; prescription expenditures

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; ARTICLE; CANCER SURVIVOR; CONTROLLED STUDY; ETHNICITY; FEMALE; GENDER; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTPATIENT; PRIORITY JOURNAL; UNITED STATES;

ADULT; COST OF ILLNESS; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SURVIVORS;

EID: 79958778576     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25835     Document Type: Article

References (24)

1. Office of Cancer Survivorship, National Cancer Institute. About cancer survivorship research: survivorship definitions. Bethesda, MD: National Cancer Institute; 2010. Accessed June 15, 2010.
2. Office of Cancer Survivorship, National Cancer Institute. Estimated US cancer prevalence counts: who are our cancer survivors in the US?. Bethesda, MD: National Cancer Institute; 2010. Accessed June 15, 2010.
3. Hewitt M, Greenfield S, Stoval E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academy Press; 2005.
4. Adler NE, Page AEK, eds. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Washington, DC: National Academy Press; 2008.
5. Rowland J., Cancer survivorship-United States, 1971-2001. MMWR Weekly. 2004; 53: 526-529.
6. Ganz PA., Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr. 2001; 30: 130-134.
7. Litwin MS., Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Curr Opin Urol. 2003; 13: 153-156. (Pubitemid 36288347)
8. Hewitt M, Herdman R, Holland J, eds. Meeting Psychosocial Needs of Women with Breast Cancer (report of the National Cancer Policy Board/Institute of Medicine and National Research Council). Washington, DC: National Academy Press; 2004.
9. Kornblith AB., Psychosocial adaptation of cancer survivors. In:, Holland JC, ed. Psycho-Oncology. New York: Oxford University Press, 1998: 223-241.
10. Yabroff KR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009; 47 (suppl): S64-S69.
11. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40 (suppl): 104-117.
12. Tangka FK, Torgdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA., Cancer treatment cost in the United States, Cancer. 2010; 116: 3477-3484.
13. Thorpe KE, Howard D., Health insurance and spending among cancer patients. Health Aff. 2003; W3: 189-198.
14. Soni A., The Five Most Costly Conditions 2000 and 2004: National Estimates for the Civilian Non-Institutionalized Population. MEPS Statistical Brief No. 167. Rockville MD: Agency for Healthcare Research and Quality; 2007.
15. Howard DH, Molinari NA, Thorpe KE., National estimates of medical costs incurred by nonelderly cancer patients. Cancer. 2004; 100: 883-891. (Pubitemid 38222846)
16. Ezzati-Rice TM, Rohde F, Greenblatt J., Sample Design of the Medical Expenditure Panel Survey Household Component, 1998-2007. Methodology Report No. 22. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
17. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
18. Office of the Actuary, Centers for Medicare and Medicaid Services. National Health Expenditures Accounts: Definitions, Sources, and Methods, 2008. Baltimore, MD: Centers for Medicare and Medicaid Services; 2008.
19. Rosenbaum P, Rubin D., The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
20. Leuven E, Sianesi B,. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Version 3.0.0. Statistical software components series. Chestnut Hill, MA: Department of Economics, Boston College; 2003. Accessed December 6, 2010.
21. Angrist JD., Estimation of limited dependent variable models with dummy endogenous regressors: simple strategies for empirical practice. J Business Econ Stat. 2001; 19: 2-16. (Pubitemid 33586932)
22. Fojo T, Grady C., How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101: 1044-1048.
23. Johnson A., Cancer drugs' cost-effectiveness questioned. Wall Street Journal. July 2, 2009. Accessed June 15, 2010.
24. Szabo L., Prices soar for cancer drugs. USA Today. July 10, 2006. Accessed June 15, 2010.